German family-owned pharma major Boehringer Ingelheim on Friday revealed that its Jascayd (nerandomilast) tablets has now ...

The US Food and Drug Administration (FDA) has approved Cytokinetics’ Myqorzo (aficamten) for the treatment of adults with ...

While it may have been a chaotic year for the US Food and Drug Administration (FDA) due to layoffs, leadership changes and ...

Danish clinical-stage techbio Evaxion today revealed it has been informed that MSD (tradename of Merck & Co outside the USA ...

US radioisotope producer Niowave has expanded its supply agreement with British pharma AstraZeneca (LSE: AZN) to a 10-year ...

The US president has signed an Executive Order directing federal agencies to move more quickly toward rescheduling marijuana ...

Syremis Therapeutics, a Tel Aviv, Israel, and Boston, USA-based clinical-stage biopharma developing novel medicines to make a ...

Japanese biotech Nxera Pharma (TSE: 4565) has revealed that Germany’s Boehringer Ingelheim opted not to exercise its ...

Iceland-based biosimilars developer Alvotech and a US affiliate of Israel’s Teva Pharmaceutical Industries, today announced ...

Orum Therapeutics, a Korea-listed biotech developing degrader-antibody conjugates (DACs), has secured 145 billion South ...

Shares of Amicus Therapeutics shot up 30% to $10.89 in pre-market activity today, on the news of a takeover offer from fellow USA-based BioMarin.

South Korean biosimilars specialist Celltrion said the European medicines regulator has adopted a positive opinion for an autoinjector version of SteQeyma, its biosimilar to Stelara (ustekinumab).